Bone resorption
Dotaz
Zobrazit nápovědu
Bone, ISSN 8756-3282 Vol. 44, suppl. 1, May 2009
185 s. : il., tab. ; 28 cm
- MeSH
- Albers-Schönbergova nemoc MeSH
- endokrinologie metody MeSH
- kongresy jako téma MeSH
- metabolické nemoci kostí MeSH
- nádory kostí MeSH
- resorpce kosti MeSH
- Publikační typ
- abstrakt z konference MeSH
- Konspekt
- Ortopedie. Chirurgie. Oftalmologie
- NLK Obory
- ortopedie
Osteoporosis international, ISSN 0937-941X vol. 14, suppl. 3, 2003
A4, S76 s. : il., grafy ; 30 cm
- MeSH
- kosti a kostní tkáň metabolismus ultrastruktura MeSH
- osteoporóza farmakoterapie MeSH
- patologická demineralizace kostí MeSH
- stroncium MeSH
- Publikační typ
- kongresy MeSH
- sborníky MeSH
- Konspekt
- Ortopedie. Chirurgie. Oftalmologie
- NLK Obory
- ortopedie
- vnitřní lékařství
Monographs of the Mario Negri Institute for Pharmacological Research
205 s. : il.
Bone turnover markers (BTMs) are released during the bone remodelling cycle and are measurable in blood or urine, reflecting bone remodelling rate. They have been useful in elucidating the pharmacodynamics and effectiveness of osteoporosis medication in clinical trials and are increasingly used in routine clinical management of osteoporosis, especially for monitoring therapy, in addition to their use in other metabolic bone disease such as Paget's disease of bone and osteomalacia. Serum β isomerised C-terminal telopeptide of type I collagen and pro-collagen I N-terminal propeptide have been designated as reference BTMs for use in osteoporosis. In addition, bone-specific isoenzyme of alkaline phosphatase (B-ALP) secreted by osteoblasts and tartrate-resistant acid phosphatase 5b (TRACP-5b) secreted by osteoclasts are also found to be specific markers of bone formation and resorption, respectively. The concentrations of the latter enzymes in blood measured by immunoassay provide reliable measures of bone turnover even in the presence of renal failure. B-ALP is recommended for use in the assessment of renal bone disease of chronic kidney disease, and TRACP-5b shows promise as a marker of bone resorption in that condition. BTMs in blood do not suffer from biological variation to the same extent as the older BTMs that were measured in urine. Appropriate patient preparation and sample handling are important in obtaining accurate measures of BTMs for clinical use. Reference change values and treatment targets have been determined for the reference BTMs for their use in monitoring osteoporosis treatment. Further ongoing studies will enhance their clinical applications.
- MeSH
- aminokyseliny MeSH
- biologické markery moč MeSH
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- novorozenec MeSH
- osteoporóza MeSH
- předškolní dítě MeSH
- referenční hodnoty MeSH
- resorpce kosti MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- přehledy MeSH
- srovnávací studie MeSH
- MeSH
- dospělí MeSH
- finanční podpora výzkumu jako téma MeSH
- homeostáza MeSH
- kostní denzita MeSH
- lidé středního věku MeSH
- lidé MeSH
- matematické výpočty počítačové MeSH
- osteoporóza diagnóza etiologie prevence a kontrola MeSH
- remodelace kosti MeSH
- resorpce kosti MeSH
- senioři MeSH
- teoretické modely MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- srovnávací studie MeSH
- MeSH
- čelisti MeSH
- dospělí MeSH
- lidé MeSH
- nemoci parodontu diagnóza MeSH
- resorpce kosti MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
The aim of this study was to assess the effects of the antiresorptive treatments of alendronate (ALN), risedronate (RIS) and raloxifene (RLX) on the response of bone to endogenous parathyroid hormone (PTH) induced by acute hypocalcemia. Forty women (age, 55-80 years) with postmenopausal osteoporosis (treated with ALN, RIS and RLX or untreated-control group) were given infusions of sodium ethylenediaminetetraacetic acid (EDTA; 10 mg/kg of body weight). Serum ionized calcium (iCa), plasma intact PTH and marker of bone resorption, serum beta C-terminal telopeptide of type I collagen (beta-CTX; beta CrossLaps) were followed for 180 min. In all women, decrease in serum iCa following the EDTA load resulted in an acute increase in serum PTH. Between 60 and 180 min, plasma PTH in the ALN and RIS treated women remained significantly higher than in the control group. The integrated beta-CTX responses (area under curves, AUCs) to peaks of PTH were significantly lower in the ALN treated women than in those treated with RIS, RLX or control group. There was no significant difference in beta-CTX AUC response to PTH between RIS, RLX and control women. Taken together, these findings suggest that in women with postmenopausal osteoporosis treated with ALN, a substantial reduction of bone turnover blunts the acute bone resorbing effect of endogenous PTH.
- MeSH
- alendronát terapeutické užití MeSH
- biologické markery krev MeSH
- chelátory farmakologie MeSH
- EDTA farmakologie MeSH
- financování organizované MeSH
- hypokalcemie chemicky indukované MeSH
- inhibitory kostní resorpce terapeutické užití MeSH
- kolagen typu I účinky léků MeSH
- kyselina etidronová analogy a deriváty terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- parathormon metabolismus MeSH
- peptidy účinky léků MeSH
- plocha pod křivkou MeSH
- postmenopauzální osteoporóza farmakoterapie krev MeSH
- raloxifen hydrochlorid terapeutické užití MeSH
- remodelace kosti účinky léků MeSH
- resorpce kosti metabolismus MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
